Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No.

× No keyword cloud information.

14 in total

1. Might money spent on statins be better spent?

Authors: Arnold J Jenkins
Journal: BMJ Date: 2003-10-18

2. Low and lowered cholesterol and total mortality.

Authors: Michael H Criqui; Beatrice A Golomb
Journal: J Am Coll Cardiol Date: 2004-09-01 Impact factor: 24.094

3. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems.

Authors: H Sinzinger; J O'Grady
Journal: Br J Clin Pharmacol Date: 2004-04 Impact factor: 4.335

4. Central nervous system and limb anomalies in case reports of first-trimester statin exposure.

Authors: Robin J Edison; Maximilian Muenke
Journal: N Engl J Med Date: 2004-04-08 Impact factor: 91.245

5. Are lipid-lowering guidelines evidence-based?

Authors: J Abramson; J M Wright
Journal: Lancet Date: 2007-01-20 Impact factor: 79.321

Review 6. Statin-induced apoptosis and skeletal myopathy.

Authors: Amie J Dirks; Kimberly M Jones
Journal: Am J Physiol Cell Physiol Date: 2006-08-02 Impact factor: 4.249

7. Statins for primary prevention: at what coronary risk is safety assured?

Authors: P R Jackson; E J Wallis; I U Haq; L E Ramsay
Journal: Br J Clin Pharmacol Date: 2001-10 Impact factor: 4.335

8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors:
Journal: Lancet Date: 1994-11-19 Impact factor: 79.321

9. Report of the Conference on Low Blood Cholesterol: Mortality Associations.

Authors: D Jacobs; H Blackburn; M Higgins; D Reed; H Iso; G McMillan; J Neaton; J Nelson; J Potter; B Rifkind
Journal: Circulation Date: 1992-09 Impact factor: 29.690

Review 10. Drug treatment of hyperlipidemia in women.

Authors: Judith M E Walsh; Michael Pignone
Journal: JAMA Date: 2004-05-12 Impact factor: 56.272

5 in total

Review 1. Cardiovascular disease and primary ovarian insufficiency.

Authors: Melissa Wellons
Journal: Semin Reprod Med Date: 2011-10-03 Impact factor: 1.303

2. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.

Authors: Quynh A Truong; Sabina A Murphy; Carolyn H McCabe; Annemarie Armani; Christopher P Cannon
Journal: Circ Cardiovasc Qual Outcomes Date: 2011-04-12

3. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.

Authors: Samia Mora; Robert J Glynn; Judith Hsia; Jean G MacFadyen; Jacques Genest; Paul M Ridker
Journal: Circulation Date: 2010-02-22 Impact factor: 29.690

Review 4. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective.

Authors: Richard Kones
Journal: Drug Des Devel Ther Date: 2010-12-09 Impact factor: 4.162

5. Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.

Authors: Beth L Abramson; Pascale Benlian; Mary E Hanson; Jianxin Lin; Arvind Shah; Andrew M Tershakovec
Journal: Lipids Health Dis Date: 2011-08-22 Impact factor: 3.876

5 in total